While the current study investigated tau-PET as a predictor of cognitive decline for a selected set of cognitive domains typically affected in AD [47] our proposed methodological framework can be applied for mapping tau-PET to other cognitive or non-cognitive domains, which may motivate future efforts to investigate tau-PET for predicting patient-centered disease trajectories in AD. Here, MAPT is linked to Alzheimer disease.